Phathom Pharmaceuticals

About:

Phathom Pharmaceuticals is a biopharmaceutical company.

Website: https://www.phathompharma.com/

Top Investors: Hercules Capital, RA Capital Management, Biotechnology Value Fund, Janus Henderson Investors, Silicon Valley Bank

Description:

Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the clinical drug candidate vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders. Phathom has assembled a leading team of seasoned gastrointestinal and pharmaceutical industry experts with proven experience developing and commercializing highly innovative therapies.

Total Funding Amount:

$660M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Florham Park, New Jersey, United States

Founded Date:

2018-01-01

Contact Email:

info(AT)phathompharma.com

Founders:

Aditya Kohli, Azmi Nabulsi, David Socks, Roger Ulrich, Tadataka Yamada

Number of Employees:

101-250

Last Funding Date:

2024-08-19

IPO Status:

Public

© 2025 bioDAO.ai